SG11201701710SA - Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody - Google Patents

Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody

Info

Publication number
SG11201701710SA
SG11201701710SA SG11201701710SA SG11201701710SA SG11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA
Authority
SG
Singapore
Prior art keywords
disorder
disease
treating
methods
combination
Prior art date
Application number
SG11201701710SA
Other languages
English (en)
Inventor
Abderrahim Fandi
David Reiser
Debora Barton
Damir Begic
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11201701710SA publication Critical patent/SG11201701710SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201701710SA 2014-09-08 2015-09-08 Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody SG11201701710SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462047463P 2014-09-08 2014-09-08
PCT/US2015/048812 WO2016040238A1 (en) 2014-09-08 2015-09-08 Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody

Publications (1)

Publication Number Publication Date
SG11201701710SA true SG11201701710SA (en) 2017-04-27

Family

ID=54150681

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701710SA SG11201701710SA (en) 2014-09-08 2015-09-08 Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody

Country Status (12)

Country Link
US (1) US20160067336A1 (enExample)
EP (1) EP3191104A1 (enExample)
JP (1) JP2017526700A (enExample)
KR (1) KR20170045237A (enExample)
CN (1) CN106604745A (enExample)
AU (1) AU2015315435A1 (enExample)
CA (1) CA2960490A1 (enExample)
EA (1) EA201790543A1 (enExample)
IL (1) IL250887A0 (enExample)
MX (1) MX2017002875A (enExample)
SG (1) SG11201701710SA (enExample)
WO (1) WO2016040238A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
CA2978942A1 (en) * 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
US11287428B2 (en) 2016-03-16 2022-03-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
SG11201810951RA (en) * 2016-06-10 2019-01-30 Io Therapeutics Inc Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2018007554A1 (en) * 2016-07-06 2018-01-11 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
MX2019003755A (es) * 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
IL266424B2 (en) 2016-11-02 2023-09-01 Engmab Sarl A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma
EP3589659B1 (en) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinations for use in the treatment of cancer
CA3060581A1 (en) * 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ， インコーポレイテッド 併用療法
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
NZ760459A (en) 2017-07-13 2023-05-26 Io Therapeutics Inc Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
WO2019046591A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY
US20220008383A1 (en) * 2018-11-13 2022-01-13 Amy Yee Compositions and methods of enhancing immunotherapies
CN113543806A (zh) * 2019-03-04 2021-10-22 北卡罗莱纳州立大学 结合表观遗传调控和免疫检查点阻断的药物递送
JP2022537384A (ja) 2019-06-20 2022-08-25 セルジーン コーポレーション ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
WO2021206831A1 (en) * 2020-04-07 2021-10-14 Metanoi Therapeutics, Inc. Ethanolamine formulation for treating epithelial ovarian carcinoma
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
MX2011003195A (es) * 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
JP6063628B2 (ja) * 2009-02-10 2017-01-18 セルジーン インターナショナル サルル ５−アザシチジンを用いる、非小細胞肺癌の治療方法
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20140357567A1 (en) * 2011-11-01 2014-12-04 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
US11083743B2 (en) * 2013-02-21 2021-08-10 Michele Maio DNA hypomethylating agents for cancer therapy
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation

Also Published As

Publication number Publication date
WO2016040238A1 (en) 2016-03-17
US20160067336A1 (en) 2016-03-10
IL250887A0 (en) 2017-04-30
EA201790543A1 (ru) 2017-07-31
KR20170045237A (ko) 2017-04-26
MX2017002875A (es) 2017-05-30
AU2015315435A1 (en) 2017-03-23
CN106604745A (zh) 2017-04-26
JP2017526700A (ja) 2017-09-14
CA2960490A1 (en) 2016-03-17
EP3191104A1 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
IL250887A0 (en) Methods of treating a disease or disorder by an oral formulation of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
IL275092A (en) Methods for treating Crohn's disease using an anti-IL-23 antibody
ZA201703290B (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
IL264502B1 (en) Anti-cd3 antibody formulations
IL247478A0 (en) Bispecific antibodies against her2
IL246661B (en) Human antibodies to pd–l1
PL3331910T3 (pl) Przeciwciała monoklonalne przeciwko ludzkiemu antygenowi dojrzewania limfocytów B (BCMA)
DK3240805T3 (da) Bispecifik or-gate kimærisk antigenreceptor, som reagerer på cd19 og cd20
SI3154583T1 (sl) Humana monoklonalna protitelesa na gangliozid GD2
PL3390450T3 (pl) Humanizowane przeciwciało anty-cd28 formułowane do podawania ludziom
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
SG11201703292VA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
IL272676B (en) Bispecific antibodies against il-4 and il-13
GB201600324D0 (en) VPA medicine intermediate two methyl propyl cyanide synthesis method
GB201421735D0 (en) Humanized gut microbiota
GB201509493D0 (en) Therapeutic antibody